Key facts, as of
As of September 29, 2026, Gilead Sciences (GILD) trades at $151.28, up 34.3% over the past year. Its 52-week range runs from $108.46 to $157.29; the price is 3.8% below that high. It sits 11.0% above its 200-day average of $136.31, the usual sign of a long-term uptrend. Its 30-day volatility is 19.9% annualized, which we rate medium risk. It has a dividend yield of 2.15%.
Cite: Portfolio Terminal, "Gilead Sciences (GILD) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/gild
Where it trades today
trading 88% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- GILD carries a beta of 0.35, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- GILD is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for GILD come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for GILD. Last refresh: Sep 29, 2026, 10:33 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Gilead Sciences does
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.…
Employees
17,000
Industry
Drug Manufacturers - General
Headquarters
Foster City, United States
What analysts expect
GILD carries a buy consensus from 26 analysts, with an average price target of $158.65 versus $151.28 today (+4.9%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
GILD generated $30.46B in trailing revenue (10.2% year over year), with a -10.6% net margin, and $9.77B of free cash flow, against $21.36B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $29.44B | $23.21B | $11.70B | $8.51B | $6.84 | $9.46B |
| 2024 | $28.75B | $22.50B | $10.60B | $480.00M | $0.38 | $10.30B |
| 2023 | $27.12B | $20.62B | $8.84B | $5.67B | $4.54 | $7.42B |
| 2022 | $27.28B | $21.62B | $10.97B | $4.59B | $3.66 | $8.34B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
GILD beside the healthcare names it is usually measured against.
What the chart is saying
In an uptrend, 3.8% under its 1-year high with no resistance above.
uptrend- Price is 6.4% above its 50-day average and 11.0% above its 200-day.
- The 50-day crossed above the 200-day on 2026-08-27 (a “golden cross”).
- RSI at 59 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $142.99 (-5.5%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is GILD a good buy right now?
Gilead Sciences operates in the Healthcare sector. Current risk level is Medium based on 19.9% volatility.
Does GILD pay dividends?
Yes, Gilead Sciences offers a dividend yield of 2.15%. That is roughly $3.25 per share a year.
How volatile is GILD?
With 30-day annualized volatility of 19.9% and beta of 0.35, GILD is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for GILD?
The average analyst price target for Gilead Sciences (GILD) is $158.65 based on 26 analyst estimates, about 4.9% above the current price of $151.28. The published range runs from $123.00 to $180.00.
How much revenue does GILD generate?
Gilead Sciences reported $30.46B in trailing twelve-month revenue. Revenue growth is running at 10.2% year over year. Net margin sits at -10.6%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare GILD with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.